Thermo Fisher Scientific earnings release, July 23, 2026

Thermo Fisher Scientific Inc. (TMO) · Form 8-K, Item 2.02 · Filed · SEC filing

News

Thermo Fisher Scientific Reports Second Quarter 2026 Results

Revenue Grew 10% Including 5% Organic Revenue Growth

Grew GAAP Diluted EPS 9% and Adjusted EPS 13%

Customer Activity Across Our End Markets Continued to Strengthen

WALTHAM, Mass.

(July 23, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026.

Second Quarter Highlights

• Second quarter revenue grew 10% to $11.99 billion

• Second quarter GAAP diluted earnings per share (EPS) grew 9% to $4.68

• Second quarter adjusted EPS grew 13% to $6.03

“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellent execution and the power of our PPI Business System,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “Our end markets continue to strengthen and we're making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain.”

Casper added, “At the halfway point of the year, we are well positioned to deliver a great 2026 and build an even brighter future for our company.”

Growth Strategy and Capital Deployment

• Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. At the American Society for Mass Spectrometry conference, we introduced next-generation Orbitrap platforms with AI-driven analytics. Highlights include the Thermo Scientific™ Orbitrap™ Tribrid™ Apex Mass Spectrometer, which enables researchers to study complex biology across multiomics, structural biology, biopharma characterization and small-molecule analysis on a single system, and the Thermo Scientific™ Orbitrap™ Excedion™ Mass Spectrometer, which enables scientists to identify hard-to-detect molecules in drug development, reducing risk and accelerating time to market. We also introduced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation PCR system designed to improve workflow flexibility, speed and reproducibility for molecular biology laboratories.

• Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers. During the quarter, we opened our flagship U.S. Bioprocess Design Center in Plainville, Massachusetts, expanding our global network of collaborative innovation hubs enabling pharma and biotech customers to accelerate drug development and optimize manufacturing. We also announced a strategic collaboration with Precision Health Research, Singapore to support the PRECISE-SG100K population health study, leveraging our integrated proteomics capabilities, including Olink® technology and the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometry system, to advance precision medicine.

• Continued to successfully execute our capital deployment strategy. During the quarter, we announced the divestiture of our microbiology business and repurchased $1.0 billion of stock.

Financial Results

Revenue for the second quarter of 2026 grew 10% to $11.99 billion, versus $10.85 billion in the same quarter of 2025. Organic revenue growth was 5%.

GAAP Earnings Results

GAAP diluted EPS in the second quarter of 2026 was $4.68, 9% growth versus the second quarter of 2025. GAAP operating income for the second quarter of 2026 was $2.09 billion, 14% higher than the year-ago quarter. GAAP operating margin was 17.4%, compared with 16.9% in the second quarter of 2025.

Non-GAAP Earnings Results

Adjusted EPS for the second quarter of 2026 was $6.03, 13% growth versus the second quarter of 2025. Adjusted operating income for the second quarter of 2026 was $2.73 billion, 15% higher than the year-ago quarter. Adjusted operating margin was 22.8%, compared with 21.9% in the second quarter of 2025.

Annual Guidance for 2026

The company will provide updated 2026 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.

Use of Non-GAAP Financial Measures

Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, and organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.

Note on Presentation

Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Conference Call

Thermo Fisher Scientific will hold its earnings conference call today, July 23, 2026, at 8:30 a.m. Eastern Time. During the call, the company will discuss its financial performance, as well as future expectations.

The call will be webcast live on the “Investors” section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 461-5787 within the U.S. or +1 (585) 542-9983 outside the U.S. The access code is 835035800.

The earnings press release and related information can also be found on the Investor Relations section of our website, under the heading “Financials”. A replay of the call will be available under “News, Events & Presentations” through Tuesday, October 20, 2026.

About Thermo Fisher Scientific... (truncated), we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Safe Harbor Statement

Financial statements

Income Statement

### (in millions)

Three months ended – June 27,Three months ended – % ofThree months ended – June 28,Three months ended – % of
Condensed Consolidated Statements of Income (unaudited)(Dollars in millions except per share amounts)2,026Revenues2,025Revenues
Condensed Consolidated Statements of Income (unaudited)Revenues11,99410,855
Costs and operating expenses:Cost of revenues (a)7,05158.8%6,37858.8%
Costs and operating expenses:Selling, general and administrative expenses (b)1,90915.9%1,77916.4%
Costs and operating expenses:Amortization of acquisition-related intangible assets4854.0%4294.0%
Costs and operating expenses:Research and development expenses3643.0%3523.2%
Costs and operating expenses:Restructuring and other costs (c)980.8%820.8%
Costs and operating expenses:Total costs and operating expenses9,90782.6%9,02183.1%
Costs and operating expenses:Operating income2,08717.4%1,83416.9%
Costs and operating expenses:Interest income207297
Costs and operating expenses:Interest expense-401-404
Costs and operating expenses:Other income/(expense) (d)31-19
Costs and operating expenses:Income before income taxes1,9241,709
Costs and operating expenses:Benefit from/(provision for) income taxes (e)-167-92
Costs and operating expenses:Equity in earnings/(losses) of unconsolidated entities-152
Costs and operating expenses:Net income1,7411,618
Costs and operating expenses:Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest (f)52
Costs and operating expenses:Net income attributable to Thermo Fisher Scientific Inc.1,73614.5%1,61714.9%
Earnings per share attributable to Thermo Fisher Scientific Inc.:Basic4.684.28
Earnings per share attributable to Thermo Fisher Scientific Inc.:Diluted4.684.28
Weighted average shares:Basic371378
Weighted average shares:Diluted371378
Reconciliation of adjusted operating income and adjusted operating marginGAAP operating income2,08717.4%1,83416.9%
Reconciliation of adjusted operating income and adjusted operating marginCost of revenues adjustments (a)280.2%100.1%
Reconciliation of adjusted operating income and adjusted operating marginSelling, general and administrative expenses adjustments (b)360.3%200.2%
Reconciliation of adjusted operating income and adjusted operating marginRestructuring and other costs (c)980.8%820.8%
Reconciliation of adjusted operating income and adjusted operating marginAmortization of acquisition-related intangible assets4854.0%4294.0%
Reconciliation of adjusted operating income and adjusted operating marginAdjusted operating income (non-GAAP measure)2,73522.8%2,37521.9%
Reconciliation of adjusted net incomeGAAP net income attributable to Thermo Fisher Scientific Inc.1,7361,617
Reconciliation of adjusted net incomeCost of revenues adjustments (a)2810
Reconciliation of adjusted net incomeSelling, general and administrative expenses adjustments (b)3620
Reconciliation of adjusted net incomeRestructuring and other costs (c)9882
Reconciliation of adjusted net incomeAmortization of acquisition-related intangible assets485429
Reconciliation of adjusted net incomeOther income/expense adjustments (d)-315
Reconciliation of adjusted net incomeIncome taxes adjustments (e)-127-133
Reconciliation of adjusted net incomeEquity in earnings/losses of unconsolidated entities15-2
Reconciliation of adjusted net incomeNoncontrolling interests adjustments (f)-1
Reconciliation of adjusted net incomeAdjusted net income (non-GAAP measure)2,2412,026
Reconciliation of adjusted earnings per shareGAAP diluted EPS attributable to Thermo Fisher Scientific Inc.4.684.28
Reconciliation of adjusted earnings per shareCost of revenues adjustments (a)0.070.03
Reconciliation of adjusted earnings per shareSelling, general and administrative expenses adjustments (b)0.10.05
Reconciliation of adjusted earnings per shareRestructuring and other costs (c)0.270.22
Reconciliation of adjusted earnings per shareAmortization of acquisition-related intangible assets1.311.14
Reconciliation of adjusted earnings per shareOther income/expense adjustments (d)-0.080.01
Reconciliation of adjusted earnings per shareIncome taxes adjustments (e)-0.34-0.35
Reconciliation of adjusted earnings per shareEquity in earnings/losses of unconsolidated entities0.04-0.01
Reconciliation of adjusted earnings per shareNoncontrolling interests adjustments (f)0
Reconciliation of adjusted earnings per shareAdjusted EPS (non-GAAP measure)6.035.36
Reconciliation of free cash flowGAAP net cash provided by operating activities2,1251,399
Reconciliation of free cash flowPurchases of property, plant and equipment-450-294
Reconciliation of free cash flowProceeds from sale of property, plant and equipment31
Reconciliation of free cash flowFree cash flow (non-GAAP measure)1,6781,105

Income Statement

Business Segment Information — ### (in millions)

Three months ended – June 27, – 2026Three months ended – % of – RevenuesThree months ended – June 28, – 2025Three months ended – % of – Revenues
Life Sciences Solutions2,81523.5%2,49923.0%
Analytical Instruments1,84715.4%1,72815.9%
Specialty Diagnostics1,20510.0%1,13410.4%

Income Statement

Consolidated depreciation expense is $331 and $256 in 2026 and 2025, respectively. (in millions)

Six months ended – June 27,Six months ended – % ofSix months ended – June 28,Six months ended – % of
Condensed Consolidated Statements of Income (unaudited)(Dollars in millions except per share amounts)2,026Revenues2,025Revenues
Condensed Consolidated Statements of Income (unaudited)Revenues22,99921,219
Costs and operating expenses:Cost of revenues (a)13,58059.0%12,43558.6%
Costs and operating expenses:Selling, general and administrative expenses (b)3,70716.1%3,50016.5%
Costs and operating expenses:Amortization of acquisition-related intangible assets9154.0%8594.0%
Costs and operating expenses:Research and development expenses7003.0%6953.3%
Costs and operating expenses:Restructuring and other costs (c)1470.6%1800.9%
Costs and operating expenses:Total costs and operating expenses19,04982.8%17,66883.3%
Costs and operating expenses:Operating income3,95017.2%3,55116.7%
Costs and operating expenses:Interest income440501
Costs and operating expenses:Interest expense-755-707
Costs and operating expenses:Other income/(expense) (d)22-16
Costs and operating expenses:Income before income taxes3,6583,329
Costs and operating expenses:Benefit from/(provision for) income taxes (e)-238-187
Costs and operating expenses:Equity in earnings/(losses) of unconsolidated entities-23-12
Costs and operating expenses:Net income3,3973,130
Costs and operating expenses:Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest (f)106
Costs and operating expenses:Net income attributable to Thermo Fisher Scientific Inc.3,38714.7%3,12414.7%
Earnings per share attributable to Thermo Fisher Scientific Inc.:Basic9.118.27
Earnings per share attributable to Thermo Fisher Scientific Inc.:Diluted9.18.26
Weighted average shares:Basic372378
Weighted average shares:Diluted372378
Reconciliation of adjusted operating income and adjusted operating marginGAAP operating income3,95017.2%3,55116.7%
Reconciliation of adjusted operating income and adjusted operating marginCost of revenues adjustments (a)420.2%210.1%
Reconciliation of adjusted operating income and adjusted operating marginSelling, general and administrative expenses adjustments (b)790.3%340.2%
Reconciliation of adjusted operating income and adjusted operating marginRestructuring and other costs (c)1470.6%1800.9%
Reconciliation of adjusted operating income and adjusted operating marginAmortization of acquisition-related intangible assets9154.0%8594.0%
Reconciliation of adjusted operating income and adjusted operating marginAdjusted operating income (non-GAAP measure)5,13322.3%4,64421.9%
Reconciliation of adjusted net incomeGAAP net income attributable to Thermo Fisher Scientific Inc.3,3873,124
Reconciliation of adjusted net incomeCost of revenues adjustments (a)4221
Reconciliation of adjusted net incomeSelling, general and administrative expenses adjustments (b)7934
Reconciliation of adjusted net incomeRestructuring and other costs (c)147180
Reconciliation of adjusted net incomeAmortization of acquisition-related intangible assets915859
Reconciliation of adjusted net incomeOther income/expense adjustments (d)-294
Reconciliation of adjusted net incomeIncome taxes adjustments (e)-296-256
Reconciliation of adjusted net incomeEquity in earnings/losses of unconsolidated entities2312
Reconciliation of adjusted net incomeNoncontrolling interests adjustments (f)-1
Reconciliation of adjusted net incomeAdjusted net income (non-GAAP measure)4,2693,976
Reconciliation of adjusted earnings per shareGAAP diluted EPS attributable to Thermo Fisher Scientific Inc.9.18.26
Reconciliation of adjusted earnings per shareCost of revenues adjustments (a)0.110.06
Reconciliation of adjusted earnings per shareSelling, general and administrative expenses adjustments (b)0.210.09
Reconciliation of adjusted earnings per shareRestructuring and other costs (c)0.40.48
Reconciliation of adjusted earnings per shareAmortization of acquisition-related intangible assets2.462.27

Income Statement

Business Segment Information — Consolidated depreciation expense is $331 and $256 in 2026 and 2025, respectively. (in millions)

Six months ended – June 27, – 2026Six months ended – % of – RevenuesSix months ended – June 28, – 2025Six months ended – % of – Revenues
Life Sciences Solutions5,45023.7%4,84022.8%
Analytical Instruments3,56315.5%3,44616.2%
Specialty Diagnostics2,34610.2%2,28210.8%
Laboratory Products and Biopharma Services12,72955.3%11,63554.8%
Eliminations-1,089-4.7%-983-4.6%
Consolidated revenues22,999100.0%21,219100.0%
Segment income and segment income marginLife Sciences Solutions1,99436.6%1,75336.2%
Segment income and segment income marginAnalytical Instruments77921.9%72421.0%
Segment income and segment income marginSpecialty Diagnostics64627.6%61026.7%
Segment income and segment income marginLaboratory Products and Biopharma Services1,71413.5%1,55713.4%
Segment income and segment income marginSubtotal reportable segments5,13322.3%4,64421.9%
Segment income and segment income marginCost of revenues adjustments (a)-42-0.2%-21-0.1%
Segment income and segment income marginSelling, general and administrative expenses adjustments (b)-79-0.3%-34-0.2%
Segment income and segment income marginRestructuring and other costs (c)-147-0.6%-180-0.9%
Segment income and segment income marginAmortization of acquisition-related intangible assets-915-4.0%-859-4.0%
Segment income and segment income marginConsolidated GAAP operating income3,95017.2%3,55116.7%

Balance Sheet

Consolidated depreciation expense is $638 and $532 in 2026 and 2025, respectively. (in millions)

June 27,December 31,
Condensed Consolidated Balance Sheets (unaudited)(In millions)2,0262,025
Current assets:Cash and cash equivalents4,0649,852
Current assets:Short-term investments253
Current assets:Accounts receivable, net9,4518,900
Current assets:Inventories5,6275,425
Current assets:Other current assets4,2244,278
Current assets:Total current assets23,36528,707
Current assets:Property, plant and equipment, net10,75510,565
Current assets:Acquisition-related intangible assets, net18,60615,838
Current assets:Other assets5,6165,871
Current assets:Goodwill54,83249,362
Current assets:Total assets113,174110,343
Current liabilities:Short-term obligations and current maturities of long-term obligations3,3683,533
Current liabilities:Other current liabilities11,70111,656
Current liabilities:Total current liabilities15,06915,189
Current liabilities:Other long-term liabilities6,1165,766
Current liabilities:Long-term obligations39,18135,852
Current liabilities:Redeemable noncontrolling interest121122
Current liabilities:Total equity52,68653,415
Current liabilities:Total liabilities, redeemable noncontrolling interest and equity113,174110,343

Cash Flow

Consolidated depreciation expense is $638 and $532 in 2026 and 2025, respectively. (in millions)

Six months ended – June 27,Six months ended – June 28,
Condensed Consolidated Statements of Cash Flows (unaudited)(In millions)2,0262,025
Operating activitiesNet income3,3973,130
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization1,5521,391
Adjustments to reconcile net income to net cash provided by operating activities:Change in deferred income taxes-466-601
Adjustments to reconcile net income to net cash provided by operating activities:Other net non-cash expenses370354
Adjustments to reconcile net income to net cash provided by operating activities:Changes in assets and liabilities, excluding the effects of acquisitions-1,537-2,151
Adjustments to reconcile net income to net cash provided by operating activities:Net cash provided by operating activities3,3172,122
Investing activitiesPurchases of property, plant and equipment-826-656
Investing activitiesProceeds from sale of property, plant and equipment1313
Investing activitiesProceeds from cross-currency interest rate swap interest settlements187134
Investing activitiesAcquisitions, net of cash acquired-8,872
Investing activitiesPurchases of investments-35-311
Investing activitiesProceeds from sales and maturities of investments2536
Investing activitiesNet proceeds from terminations of cross-currency interest rate swaps481
Investing activitiesOther investing activities, net1
Investing activitiesNet cash used in investing activities-8,797-815
Financing activitiesNet proceeds from issuance of debt5,2382,840
Financing activitiesRepayment of debt-1,412-1,625
Full release

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent reports on Form 10-K and Form 10-Q under the heading “Risk Factors.” These filings are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” These forward-looking statements are based on our current expectations and speak only as of the date of this press release. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, in the event of new information, future developments or otherwise.

###

(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. Adjusted results in 2026 also exclude $6 of transaction-related costs. Adjusted results in 2025 also exclude $5 of charges for the sale of inventory revalued at the date of acquisition.

(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, charges/credits for changes in estimates of contingent acquisition consideration, and accelerated depreciation on fixed assets to be abandoned due to facility consolidations.

(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.

(d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2026 and 2025 also exclude $6 of business interruption recoveries and $5 for settlement charges for pension plans, respectively.

(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements.

(f) Adjusted results in 2025 exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

Note:

Consolidated depreciation expense is $331 and $256 in 2026 and 2025, respectively.

(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges/(credits) for the sale of inventory revalued at the date of acquisition. Adjusted results in 2026 also exclude $9 of transaction-related costs.

(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, charges/credits for changes in estimates of contingent acquisition consideration, and accelerated depreciation on fixed assets to be abandoned due to facility consolidations.

(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.

(d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2026 and 2025 also exclude $6 of business interruption recoveries and $5 for settlement charges for pension plans, respectively.

(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements.

(f) Adjusted results in 2025 exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

Note:

Consolidated depreciation expense is $638 and $532 in 2026 and 2025, respectively.

Supplemental Information Regarding Non-GAAP Financial Measures... (truncated)the impact of acquisitions/divestitures, and/or foreign currency translation on revenues. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

• Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.

• Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs.

• Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

• The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

• The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions, transaction-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.

The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Thermo Fisher Scientific earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.